A bdominal aortic aneurysms (AAAs) comprise the tenth leading cause of death among men >65 and result in >15 000 surgical procedures annually in the United States. 1,2 Although prevalence of aneurysms is on the rise, the mechanisms that regulate aortic aneurysm formation remain unclear. 1,2 Currently, aneurysm formation is normally accompanied by destruction of the intimal layer and loss of aortic smooth muscle cell (SMC) contractile function. 3, 4 Furthermore, AAA formation is often accompanied by mural thrombus deposition, and infiltration by mesenchymal cells, processes influenced by immune regulation. 5,6 Finally, collagen and elastin extracellular matrix of the abdominal aorta is thought to undergo degradation and contribute to AAA formation via a myriad of mechanisms modulated by inflammatory cells. 5, 6 The effects of SMC apoptosis accompanied by extracellular matrix degradation of elastin and collagen lead to aneurysm formation; however, the mechanism that regulates this process and the cell-cell interactions is unknown.
injury inflammation. 15, 16 KLF4 along with Oct4, Sox2, and c-myc is also capable of reprogramming somatic cells into induced pluripotential stem cells. 17 In addition, global conditional KLF4 knockout mice demonstrated a delay in SMC phenotypic switching after carotid artery endothelial injury. 18 Because SMC phenotypic switching occurs early in AAA formation, and the mechanisms by which this occurs in aneurysm formation are unknown, our overall goal was to investigate the effects of KLF4 on SM phenotype and aneurysm disease. In the present studies, we hypothesize that KLF4 deletion results in attenuated aneurysm formation and this occurs, in part, through phenotypic modulation of SMCs.
Materials and Methods

Defining KLF4 in the Murine Elastase Aneurysm Model
Two groups of 8-to 12-week-old wild-type (WT) C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) underwent the murine aortic aneurysm model with either elastase or saline perfusion (WT elastase, WT saline) as described previously. 3, 4, [19] [20] [21] Infrarenal abdominal aortas from both groups were evaluated and harvested for tissue analysis at days 0, 3, 7, and 14.
Murine Elastase Model
Eight-to 12-week-old male mice were injected with intraperitoneal ketamine solution, perfused with elastase, and harvested as previously described, and the procedure was performed by Johnston et al. 3, 4, [19] [20] [21] The aortas (or aneurysms, when present) were harvested, and either (1) snap-frozen in liquid nitrogen for analyses by real-time polymerase chain reaction(PCR) or protein extraction, or 2) incubated overnight for histology or immunohistochemistry. Animal care and use were in accordance with the Guide for the Care and Use of Laboratory Animals. The animal protocol was approved by the University of Virginia Institutional Animal Care and Use Committee (#3634) in compliance with the Office of Laboratory Animal Welfare.
Creation of KLF4 Transgenic Mice
ERTCre+ KLF4 flx/wt mice and ERTCre+ KLF4 flx/wt mice were created by breeding ERT2 tamoxifen Cre mice with KLF4 flx/flx mice. 15, 18, 22 These mice are heterozygous knockouts of KLF4 in all cell types and are necessary to use as ERTCre+ KLF4 flx/flx mice are lethal injections as they develop epithelial and gastrointestinal defects. 15, 23 When performing experiments, ERTCre+ KLF4 flx/wt mice and their sibling age-matched controls were used when performing elastase perfusion. These mice underwent a series of 10 tamoxifen injections at 6 to 8 weeks during a 14-day period followed by 14 days of rest. These mice then underwent elastase perfusion followed by harvest 14 days later. MYHCre+ KLF4 flx/flx, MYHCre+ flx/wt, and MYHCre+ wt/ wt mice were created by breeding MYHCre+ mice 24 with KLF4 flx/ flx mice. 15, 18, 22 These mice were then back-bred together to produce the experimental and control MYHCre+ KLF4 mice. The MYHCre+ transgene has been used successfully in the past to demonstrate SM-specific knockout of various genes after tamoxifen injections. 24, 25 These mice underwent the same series of injections and injuries as mentioned for the ERTCre+ mice above.
ERTCre+ KLF4 flx/wt ApoE −/− mice were created by breeding ERTCre+ KLF4 flx/flx onto an ApoE −/− background. Once ERTCre+ KLF4 flx/flx ApoE −/− mice were created, these mice were then bred with ApoE −/− mice to produce the experimental ERTCre+ KLF4 flx/wt ApoE −/− mice and their experimental controls. These mice underwent the same series of 10 tamoxifen injections at 6 to 8 weeks followed by 2 weeks of rest and then angiotensin II infusion via osmotic pump. MYHCre+ KLF4 flx/flx, flx/wt, and wt/wt ApoE −/− mice were created by breeding MYHCre+ KLF4 flx/flx mice onto an ApoE −/− background. These mice were then back-bred together to create MYHCre+ KLF4 flx/wt ApoE −/− mice, which were then bred together to produce the experimental MYHCre+ KLF4 flx/flx and flx/wt ApoE −/− mice and their WT controls. These mice also underwent the same series of injections, 2 weeks of rest, and angiotensin II-infused osmotic pump insertion as mentioned previously.
Angiotensin II Infusion
Osmotic pumps (Alzet 2004, Durect Corp, Cupertino, CA) containing angiotensin II (1000 ng/kg per minute, Sigma Aldrich Inc, St. Louis, MO) were introduced into 10-week-old ERTCre+ KLF4 flx/wt ApoE −/− and ERTCre− KLF4 flx/wt ApoE −/− male mice as previously described. 26, 27 Mice were housed and maintained at 70°F, at 50% humidity, and in 12-hour light-dark cycles per institutional animal protocols. All mice were fed ad libitum water and placed on high-fat diet (TD 88137, Harlan Teklad Inc, Indianapolis, IN) with no restrictions on movement. Aneurysmal segments of the aortas (proximal to the renal arteries) were harvested after 28 days and processed for histology. At day 28, video micrometry measurements of the aortic wall diameter were performed in situ using a Q-Color3 Optical Camera (Olympus Corp, Center Valley, PA) using QCapture Pro Software version 6.0 (QImaging Inc, Surrey, Canada). MYHCre+ KLF4 flx/flx, flx/wt, and wt/wt ApoE −/− male mice underwent a similar procedure at 10 weeks as mentioned above. Kaplan-Meier curves and log-rank (Mantel-Cox) tests tracked the percentage survival of mice during the 28-day period.
In a second model of angiotensin II infusion, osmotic pumps containing angiotensin II were introduced into 10-week-old ERTCre+ KLF4 flx/wt and ERTCre− KLF4 flx/wt male mice as previously described. 26, 27 After angiotensin II infusion, mice received biweekly injections of anti-transforming growth factor-β (TGFβ) antibody (R&D systems). 28 After 28 days, aneurysmal segments were harvested as mentioned in the previous paragraph and percentage survival was tracked and log-rank (Mantel-Cox) tests were performed. The same procedure was performed for MYHCre+ KLF4 flx/flx, flx/wt, and wt/wt mice at 10 weeks.
mRNA and Protein Isolation
mRNA and protein were extracted from frozen aortic tissue samples with TRIzol reagent (Invitrogen, Life Technologies, Grand Island, NY) as previously described. 3, 19, 20 
Real-Time Reverse Transcription PCR Analysis
Using isolated mRNA from the mouse aortas and aortic SMCs, cDNA was synthesized using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA). Real-time reverse transcription PCR was performed using Sensifast SYBR Supermix (Bioline, Taunton, MA) with primers described previously. 10, [29] [30] [31] Target DNA was analyzed with Bio-Rad CFX Manager software (Bio-Rad, Hercules, CA) to obtain melt curves and takeoff values. Levels of mRNA were standardized either with GAPDH or 18s mRNA, which served as a housekeeping genes for comparison. All experiments were run 3× in triplicate unless otherwise mentioned.
Histology
Murine aortas were harvested at euthanasia for histology analysis after undergoing left ventricular puncture and 4% paraformaldehyde antegrade perfusion at physiological pressure. Further fixation was achieved by overnight incubation in 4% paraformaldehyde at 4°C followed by paraffin embedding and sectioning at 5 µm. After microwave antigen retrieval, antibodies were bound and detected using VectaStain Elite Kit (Vector Laboratories Inc, Burlingame, CA). Antibodies for immunohistochemical staining were anti-rat Mac2 for macrophages (1:10 000; Cedarlane Laboratories, Burlington, Canada), anti-mouse anti-neutrophil (Ly 6B.2) for neutrophils (1:10 000; AbD Serotec, Oxford, United Kingdom), anti-goat MMP2 for matrix metalloproteinase-2 (1:350; R&D Systems, Minneapolis, MN), anti-goat MMP9 for matrix metalloproteinase-9 (1:400; R&D Systems, Minneapolis, MN), and anti-mouse SMαA for SM α-actin (1:1000; Santa Cruz Biotechnology Inc, Santa Cruz, CA). Visualization color development was completed using diaminobenzidine (Dako Corporation, Carpinteria, CA) for SMαA, Mac2, antineutrophil, CD3ε, and MMP9.
Confocal immunohistochemistry was performed using immunofluorescent staining for KLF4 (1:200 dilution, R&D), macrophages with mac-2 (1:1000, Cedarlane Laboratories), SMCs with SM α-actin (1:1000, Abcam), and nuclei with 4′,6-diamidino-2-phenylindole (DAPI; 1:10 000, Invitrogen). Appropriate controls verified staining procedures. Human confocal immunofluorescent staining was performed for KLF4 (1:1000) dilution followed by TSA amplification using a TSA kit (Invitrogen), SM α-actin for SMCs (1:1000, Cy3, Sigma Alrich Corporation), and nuclei using DAPI (1:10 000; Invitrogen).
Images were acquired using AxioCam Software version 4.6 via ×10, ×40, and ×100 objectives and an AxioCam MRc camera (Carl Zeiss Inc, Thornwood, NY). Threshold-gated positive signal was detected within the AOI and quantified using ImagePro Plus version 7.0 (Media Cybernetics Inc, Bethesda, MD). Elastin degradation was quantified by counting the number of breaks per vessel and then averaged and graphed.
Cytokine Array
For the purpose of determining the effects of KLF4 total cell and SMC deletion on proinflammatory cytokines in the aortic wall, mouse cytokine arrays (R&D Systems) were performed using isolated protein from mouse aortas at day 14 according to the manufacturer's instructions (n=3 mice per group). Protein samples from each group were pooled for analysis, and all samples were run in duplicate. 19, 20 
Mouse Aortic SMC Cultures
Mouse abdominal aortic SM was isolated and cultured as previously described. 5 For siRNA transfections, cells at passages 8 to 10 were plated in all 6 wells of a 6-well plate at 1×10 5 cells per well; 24 hours later, cells were transfected with either a single siRNA to mouse KLF4 or a nontargeting control. 11, 12, 31, 32 Twenty-four hours later, mouse aortic SMCs were stimulated by elastin degradation products, phorbol ester, TGFβ, retinoic acid or interleukin (IL)-1β (Upstate Biotechnology), or representative vehicle for 24 hours as described previously. 13 Cells were harvested and RNA was extracted using the TriZol method, and reverse transcription PCR was performed as described previously. 11, 12, 32 
Chromatin Immunoprecipitation Analysis
Quantitative chromatin immunoprecipitation assays were performed as described previously. 11, 33, 34 For each in vivo experiment, 15 AAA samples were pooled into 3 sets of 5 samples each and chromatin immunoprecipitation analysis was performed. Experiments were performed in triplicate and 1 representative experiment was shown. Antibodies include polyclonal KLF4 (R&D Systems). Real-time PCR primers were designed as previously described for SM α-actin, SM22α, cFOS, and SM-MHC. 18, 34 For quantitative PCR, 2 µL of the 20-µL extracted DNA was used in 50 cycles of amplification in 3 steps: 95 o C for 15 s, 55 o C for 30 s, and 68 o C for 45 s. At the end of the amplification cycles, dissociation curves were determined to rule out signal from primer dimers and other nonspecific dsDNA species. Data were normalized to IgG immunoprecipitated DNA levels. The size of the PCR products was confirmed on a 2% agarose gel stained with ethidium bromide.
Human Tissue Harvest
Normal abdominal aortas were obtained from transplant donors, and aneurysmal aortas were taken from patients undergoing elective open AAA repair. All aortic samples were harvested from patients without evidence of known collagen vascular disease. Aortic tissue specimens were explanted, placed on ice, and then immediately snapfrozen in liquid nitrogen. Collection of human tissue was approved by the patient's written consent in compliance with the University of Virginia's Human Subjects Review Committee (HSR #13178).
Statistical Methods
Statistical analysis was performed using GraphPad Prism 5 software (GraphPad Software, La Jolla, CA). Maximal aortic dilation (%) was calculated as [maximal aortic diameter−internal control diameter]/ internal control diameter×100%. The internal control was a small segment of normal abdominal aorta just distal to the renal arteries that was above the proximal ligation. This section was not perfused with elastase, but it was susceptible to blood pressure changes from volume loss during the harvest, as well as expected animal growth over time. Values are reported as mean±SE of the mean. Aortic dilation between groups was compared using Fisher exact test. Post hoc Tukey correction was applied to determine the significance of individual comparisons with α=0.05. When groups were compared, the Fisher exact test was used for significance. Pearson correlation coefficients (R) were used to determine strength of linear dependence and are reported as R value (95% confidence interval). Differences between groups for histological grading for macrophage infiltration, neutrophil infiltration, and elastin degradation were tested with the Fisher exact test. Angiotensin II experiment differences were measured using a log-rank (Mantel-Cox) test. All assays were performed in triplicate unless stated otherwise. Blinding to experimental groups was maintained as feasible. Data are presented as mean±SEM.
Results
KLF4 Is Elevated During Experimental Aneurysm Formation
KLF4 has previously been shown to be a key regulator of endothelial vascular injury and to be key in the downregulation of SM marker gene expression. 13, 18 Therefore, we sought to determine whether KLF4 expression increases during aneurysm formation. Aortic dilation in WT mice was significantly increased after elastase perfusion compared with saline perfusion. 20 Although no differences in aortic dilation were present at day 3, aortic dilation was apparent at day 7 (61.8±4.0% with elastase versus 47.6±4.1% with saline; P<0.05) and most prominent 14 days after perfusion (90.1±3.7% with elastase versus 45.8±5.1% with saline; P<0.0001 20 ) .
At baseline, murine aortas have low levels of KLF4 expression ( Figure 1A) . Although there were no differences in KLF4 expression at 3 days, KLF4 expression at 7 and 14 days in elastase-perfused aortas increased significantly compared with saline-perfused aortas. Furthermore, by immunohistochemistry, KLF4 expression progressively increased after elastase perfusion as aortic diameter increased ( Figure 1B ; Figure IA in the online-only Data Supplement). To determine which cells types specifically expressed KLF4, confocal fluorescence microscopy was performed to evaluate macrophages, SMCs, and KLF4 7 days after elastase exposure. KLF4 colocalized primarily to intramural SMCs and macrophages ( Figure 1C ; Figure IB and IC in the online-only Data Supplement). Aortic samples from 14-day elastase-perfused aortas demonstrated decreased SM marker expression (data not shown), consistent with ours and others' previous studies. 4, 35, 36 
Heterozygous KLF4 Deletion Results in Attenuated Aneurysm Formation
With KLF4 levels upregulated in AAAs and known to alter vascular injury responses, we hypothesized that KLF4 plays a critical role in aneurysm formation. To test this, we required synthesis of unique transgenic mice because conventional KLF4 knockout mice are embryonic lethal. 23 September 10, 2013
Tamoxifen-inducible ERTCre+ KLF4 flx/wt mice and their controls were generated. These mice are total-cell tamoxifendependent KLF4 heterozygous knockouts and were necessary to use because inducible homozygous KLF4 knockouts are lethal because of epithelial skin and gastrointestinal defects. 15, 23 Heterozygous KLF4 knockout mice received 10 tamoxifen injections to induce KLF4 loss. After a 2-week recovery period, elastase perfusion was performed and mice were harvested at 14 days (Figure 2A ). Heterozygous KLF4 knockout mice had significant reduction in maximal aortic dilation compared with WT mice (ERTCre+ KLF4 flx/wt: 50.19±17.19%, n=10 versus ERTCre− KLF4 flx/wt: 72.27±27.13%, n=17; P<0.003; Figure 2B ).
Next, given the significant difference in aneurysm formation between KLF4 flx/wt ERT Cre+ mice and their controls, we examined elastin degradation and expression of SM α-actin and MAC2 into the medial cell layer at 14 days. Verhoeff-Van Gieson staining demonstrated significantly decreased elastin fragmentation in KLF4 heterozygous knockout mice ( Figure 2C and 2D), whereas SMC α-actin staining was significantly increased in ERTCre+ KLF4 flx/wt knockouts compared with WT controls ( Figure 2C Figure II in the online-only Data Supplement). The preceding data suggest that deletion of even 1 allele of KLF4 in the entire animal attenuates aneurysm formation and demonstrates that KLF4 is important for SMC marker gene expression, as well as macrophage and neutrophil recruitment into the aorta.
SM-Specific Deletion of KLF4 Attenuates Aneurysm Formation
As there are both SM and leukocyte sources of KLF4 ( Figure 1C ), we next sought to determine the contribution of SM-derived KLF4 in AAAs. To investigate this, SM-specific myosin heavy chain (MYH) Cre mice 24 were bred with KLF4 flx/flx mice to produce novel MYHCre+ KLF4 Flx/Flx, MYHCre+ KLF4 Flx/wt, and MYHCre+ KLF4 WT/WT mice ( Figure III in the online-only Data Supplement). Using a tamoxifen-elastase experimental design ( Figure 3A ), deletion of 1 or 2 alleles of SM-specific KLF4 showed significant step-wise protection from AAA formation compared with controls (MYHCre+ KLF4 Flx/Flx: 57.97±18.64%, n=18 versus KLF4 flx/wt SM-MHC: 64.83±16.84, n=8 versus MYHCre+ KLF4 WT/WT: 85.89±24.45, n=11; Figure 3B ). Elastin degradation was significantly less in heterozygous mice (MYHCre+ KLF4 flx/wt) and even greater protection in homozygous SM-deleted KLF4 mice (MYHCre+ KLF4 flx/flx; Figure 3C ). Similarly, there was evidence of increasing protection from macrophage and neutrophil inflammation in the MYHCre+ KLF4 flx/wt and flx/flx animals compared with WT animals ( Figure 3C ; Figure 
KLF4 Modulates Cytokine Expression and SM Marker Genes During Aneurysm Formation
To determine cytokines involved in AAA formation that may be modulated by KLF4, cytokine protein array analysis was performed on purified protein extracts from elastase-perfused aortic tissue harvested 14 days after perfusion. Aortic tissue from total-cell heterozygous deletion had significantly less MCP1, tumor necrosis factor-α, CCL12, and IL-23 ( Figure 4) . Conversely, there were increased levels of IL-10, a known anti-inflammatory cytokine (Figure 4 ). Interestingly, KLF4 did not modulate IL-1β CXCL12 or complement component 5A cytokine levels, which have been linked previously to experimental AAAs. 20, 37 Cytokine array analysis was also performed on aortic tissue harvested on day 14 from SM-specific homozygous KLF4deleted mice (MYHCre+ KLF4 flx/flx) and WT control mice (MYHCre+ KLF4 wt/wt). Cytokine levels of MCP1, tumor necrosis factor-α, CXCL12, and IL-23 were decreased in KLF4-deleted mice (MYHCre+ KLF4 flx/flx mice, P<0.05 per Fisher exact test for all; Figure 4 ). Moreover, SM-specific knockout of KLF4 increased IL-10 levels. KLF4 knockout in SMCs did not modulate IL-1β CCL12 or complement component 5A cytokine levels (Figure 4 ). Of interest, CXCL12 was not modulated in global heterozygous KLF4 knockout mice (ERTCre+ KLF4 flx/wt), whereas SM-specific knockout of KLF4 modulated CXCL12. Conversely, CCL12 was modulated with total-cell heterozygous knockout of KLF4, whereas KLF4 was not modulated in the SM-specific knockout of KLF4. 
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To determine whether these protein cytokine levels are reflected in changes in staining patterns, we stained total-cell heterozygous and SM-specific KLF4 knockout mice with an antibody to MCP1, a cytokine we previously documented to be highly critical in experimental AAAs. 3 Heterozygous and SM-specific knockout of KLF4 resulted in decreased MCP1 staining ( Figure V in the online-only Data Supplement). Taken together, these data indicate that KLF4 deletion decreased protein cytokine levels of several relevant inflammatory cytokines in aortic aneurysms.
siRNA to KLF4 Inhibits Downregulation of SMC Marker Genes In Vitro
Previously, KLF4 has been shown to repress SMC marker gene expression in vivo and in cultured SMC through multiple mechanisms 10, 34, 38 and most recently via directly binding to SM marker genes in vivo via the G/C repressor element to mediate transcriptional silencing after injury. 13 Currently, there is no known role for KLF4 modulation of SM marker genes during aneurysm formation. To determine whether KLF4 could mediate SMC marker gene downregulation during aneurysm formation, we isolated primary mouse abdominal aortic SMCs. We next treated these cells with siRNAs to KLF4 or control siRNAs followed by novel treatment with elastin degradation products (10 ng/mL). We verified that KLF4 mRNA expression was downregulated via reverse transcription PCR with siRNA treatment ( Figure 5A ). Second, we examined the levels of SM α-actin, SM22α, and SM-MHC levels after elastin degradation product treatment (EDP; Figure 5B -5D). All 3 SM marker genes were downregulated with treatment of EDP for 24 hours, similar to what has been seen previously with PDGF-BB or POVPC treatments. 10, 12 Importantly, transfection of siRNAs to KLF4 resulted in a lack of downregulation of SM marker genes after EDP treatment ( Figure 5B-5D ). IL-1β did not demonstrate deregulation in response to siKLF4 ( Figure 5E ). These findings are consistent with our in vivo studies and suggest that KLF4 is a key modulator of SM gene expression in vitro after treatment with elastin degradation products.
In separate experiments, we demonstrated that KLF4 seems to be important for SM marker gene downregulation in abdominal aortic SMCs after IL-1β treatment because we have shown previously that IL-1β and receptor-deleted mice are highly protected from aneurysm formation 20 ( Figure VI in the online-only Data Supplement). In additional subsequent experiments, we demonstrated that KLF4 overexpression alone seems to inhibit SM marker gene expression and that this effect is enhanced with cytokine treatment ( Figure VII 
KLF4 Binds to Promoters of SMCs In Vitro and In Vivo During Aneurysm Formation
Previously, it has been demonstrated that KLF4 binds directly to SM marker genes after PDGF-BB and POVPC treatment 13 ; however, there is no evidence to date that KLF4 modulates SM marker genes during aneurysm formation. We treated abdominal aortic mouse SMCs with elastin degradation products for 24 hours after serum starvation and then performed chromatin immunoprecipitation analysis to determine whether KLF4 binds to SM marker genes after EDP treatment ( Figure XI in the online-only Data Supplement). KLF4 significantly binds to the SM α-actin, SM22α, and SM-MHC promoters after EDP treatment ( Figure XI in the online-only Data Supplement). These data indicate that KLF4 regulates SM marker gene downregulation in vitro after EDP treatment. Importantly, KLF4 binding to SMC marker genes has never been evaluated in vivo during aneurysm formation. Thus, chromatin immunoprecipitation assays were performed on aortas from WT mice 14 days after elastase perfusion. KLF4 was found to bind specifically to the promoters of SM marker genes SM α-actin, SM22α, and SM-MHC, whereas KLF4 did not bind the cFOS promoter either before or after elastase perfusion ( Figure 6 ). Collectively, these data suggest a new model where KLF4 plays a role in the phenotypic modulation of SMCs and suggest that KLF4 plays a role in aneurysm formation via SMC modulation. 
KLF4 Deletion Attenuates Aneurysm Formation After Angiotensin II Treatment
Because the elastase perfusion model is criticized as an acute artificial (surgical) model of AAAs, we sought to determine whether KLF4 could also attenuate aneurysm formation in other established models of aneurysm formation. To determine whether KLF4 is protective of aneurysm formation, we used (1) ERTCre+ KLF4 flx/wt mice bred on an ApoE −/− background infused with angiotensin II for 28 days 26 ( Figure XIIA in the online-only Data Supplement); and (2) ERTCre+ KLF4 flx/wt mice infused with angiotensin II with a series of TGFβ injections ( Figure 7A ). 28 Kaplan-Meier curves of ERTCre+ KLF4 flx/wt-deleted mice demonstrated that KLF4 protects from death because of aneurysm rupture in both angiotensin II models of aneurysm formation ( Figure 7A and 7B; Figure VIA in the online-only Data Supplement; χ 2 =4.276; P value=0.0387 by log-rank test).
To further study the role of KLF4 in SMCs specifically, we also used these 2 models of angiotensin II aneurysm formation in MYHCre+ KLF4 flx/flx, flx/wt, wt/wt. SM-specific B A C D Figure 6 . KLF4 binds smooth muscle (SM) cell marker genes in vivo during aneurysm formation. A to D, Fourteen-day elastase and salineperfused C57/B6 mice underwent chromatin immunoprecipitation analysis for KLF4 binding in vivo during aneurysm formation. 13 A to E, Mouse abdominal aortas were isolated, the adventia and endothelial layer stripped, and the abdominal cells were placed in culture. Cells were cultured until passage 6 and SM marker genes were verified at passage 6 and then again at passage 11 for expression (data not shown). From these cultures, cells were plated at 1×10 5 cells per well and treated with siKLF4 or control, scrambled siRNA in serum-free media. 13 Twenty-four hours after transfection, cells were treated with elastin degradation products for 24 hours and then harvested, RNA extracted, and reverse transcription polymerase chain reaction performed. Brackets, A significant response (P>0.05) to treatment with elastin degradation products. *Significant downregulation of vehicle-treated cells in response to siKLF4 expression as compared with control-treated siRNA by Fisher exact test. Results are the average of 3 independent experiments performed in triplicate.
knockout of KLF4 was also protective of mouse survival during the 28-day course of aneurysm formation after angiotensin II pump insertion ( Figure 7B ; Figure XIIB in the online-only Data Supplement; χ 2 =4.886; P value=0.035 by log-rank test). These data further demonstrate the critical importance of SM-derived KLF4 in 2 additional models of aneurysm formation enhancing our findings within the elastase model of aneurysm formation.
KLF4 Is Upregulated in Human Aneurysms and Is Located in SMCs
We have seen that KLF4 is important in multiple models of murine aneurysm formation; however, we sought to determine whether KLF4 could be relevant in human aortic aneurysms. KLF4 levels were increased in human AAAs compared with healthy donor controls via reverse transcription PCR ( Figure 8A ). KLF4 staining was markedly increased in human aneurysm tissue versus controls via immunohistochemistry ( Figure 8B ). Finally, confocal immunofluorescence of SM α-actin and KLF4 demonstrated that KLF4 (red) and SM α-actin (green) are localized in the same cells within human tissue as in our experimental model ( Figure 8C ). These data suggest that KLF4 may be relevant in human aneurysm formation and, in conjunction with our experimental models, suggest that KLF4 could be considered as a novel therapeutic target in human aneurysm formation.
Discussion
Deletion of KLF4 results in decreased aortic aneurysm formation in both a heterozygous and a SM-specific knockout mouse elastase AAA model. KLF4 deletion also affected mouse survival from aneurysm rupture in 2 angiotensin II models of aneurysm formation. More importantly, we demonstrated that KLF4 attenuates SM marker gene expression and that KLF4 binds to SM marker genes in vivo during aneurysm formation. These studies document KLF4 binding to SM marker gene promoters in vivo in the context of aneurysm formation. Moreover, we verified KLF4 is upregulated in humans during aneurysm formation and that KLF4 is localized to SMCs. The present studies suggest that KLF4 contributes to suppression of SMC marker genes in response to an ever-growing range of agents in vitro and in vivo. Taken together, our results identify KLF4 as a molecular regulator of aneurysm formation that mediates SMC phenotypic switching during aneurysm formation.
A key unresolved question is the mechanism of activation of KLF4 expression in SMCs, as the cytokines that upregulate this gene are most likely key to the initiating progression of the aneurysm phenotype. Furthermore, KLF4 activation is of great interest given this gene is normally epigenetically silenced in virtually all differentiated somatic cells. 39, 40 The KLF4 promoter contains several conserved regulatory elements for AP-1, GATA-1, Sp1, nuclear factor-κB, and HLH factors 22 ; however, few studies have directly assessed activation of the KLF4 promoter under different stimuli. 30, 41 There are several relevant unresolved issues regarding mechanisms responsible for activation of KLF4 during aneurysm formation. First, few studies have been published that have determined mechanisms that activate KLF4 on vascular injury or disease. These mechanisms may be key to blocking upregulation of KLF4, and their inhibition could represent a reasonable drug target against aneurysm formation. Second, the mechanisms responsible for controlling the different roles of KLF4 in various cell types during vascular injury and disease remain unclear and at times contradictory. It is possible that post-translational modifications, such as differential mRNA splicing, or chemical modifications, such as sumoylation or acetylation, regulate effects of KLF4 in different cell types. It has been shown that TGFβ-induced expression of SM α-actin in cultured SMCs is mediated, in part, through inactivation of KLF4 through protein sumoylation. 42 
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September 10, 2013 in aneurysm formation may pose a challenge. Alternatively, targeting the down-stream effects of KLF4 activation could also be considered. Third, other Kruppel-like factors may be involved in regulating aneurysm formation. For example, KLF2 has been shown to have a profound role in atherosclerosis, 43 and future investigation will merit studying both KLF2's role during aneurysm formation and the interplay among multiple KLFs. In summary, further studies are needed to determine whether these factors regulate activation of KLF4 in SMCs in vivo and if post-translational modifications regulate KLF4 function. These studies suggest that KLF4 could be a potential therapeutic target against aneurysm formation. However, there are several potential challenges associated with targeting a transcription factor as a potential drug target. Because KLF4 is a transcription factor and can have both positive and negative interactions on many different promoters in many different cell types, the challenge will be to specifically design a drug target that can modulate KLF4's negative effects on aneurysm formation. Interestingly, our use of a KLF4 heterozygous tamoxifen-dependent total knockout of KLF4 ( Figure 2 ) reflects decreases we would see with pharmacological inhibition of KLF4 and suggests that inhibition of KLF4 in all cell types would be overall beneficial for preventing aneurysm formation. However, it is unknown whether inhibition of KLF4 in humans would ultimately revert SMCs to a noninflammatory phenotype in AAAs. Another additional issue that should be considered is KLF4 is one of the transcription factors required for stem cell function. Our laboratory has demonstrated previously that stem cells seem to be proactive when added exogenously after aneurysm treatments 19 ; however, KLF4 expression during aneurysm formation seems to be detrimental for aneurysm formation. How are these 2 issues resolved within the cellular context and what sort of modulated cell type does KLF4 cause SMCs to become? These issues have to be addressed and sufficiently understood in order for KLF4 to be used as a therapeutic target for aortic aneurysms.
In summary, the present studies provide the first direct evidence that KLF4 is an important regulator of aneurysm formation specifically in SMCs. Moreover, our results support a model whereby KLF4 mediates phenotypic switching of SMCs in vivo during aneurysm formation via binding to SM marker gene promoters. Although the present studies have focused on phenotypic modulation of SMCs and KLF4 during aneurysm formation, KLF4 also may have broad significance for the overall aneurysm phenotype given that KLF4 is already known to play key roles in mediating cellular function and proliferation in other cell types. 16, 23, 39, 44 However, further studies are needed to directly test whether KLF4 play similar roles in these other cell types during aneurysm formation.
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